Ozmosi | Soblidotin Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Soblidotin

Alternative Names: soblidotin, TZT-1027
Clinical Status: Inactive
Latest Update: 2022-07-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: MAPK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Leiomyosarcoma|Synovial Sarcoma|Fibrosarcoma|Hemangiopericytoma|Liposarcoma|Soft Tissue Cancer|Rhabdomyosarcoma|Hemangiosarcoma|Liver Cancer|Bone Cancer|Sarcoma|Histiocytoma, Malignant Fibrous|Lung Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT00072228

 DAIICHI-1027A-PRT008

P1

Withdrawn

Oncology Solid Tumor Unspecified

None

2019-03-21

Treatments

2004-001108-11

 2004-001108-11

P2

Terminated

Sarcoma|Lung Cancer|Bone Cancer|Soft Tissue Cancer|Liver Cancer

2021-01-13

2022-03-12

Treatments

NCT00064220

 CDR0000310138

P2

Completed

Histiocytoma, Malignant Fibrous|Rhabdomyosarcoma|Fibrosarcoma|Liposarcoma|Hemangiosarcoma|Hemangiopericytoma|Synovial Sarcoma|Leiomyosarcoma

2005-12-01

2025-08-27

Treatments

NCT00061854

 CDR0000301749

P2

Completed

Non-Small-Cell Lung Cancer

2005-05-01

2024-02-16

Treatments

Recent News Events

Date

Type

Title

07/01/2022

PubMed

 Cytotoxicity, in silico predictions and molecular studies for androstane heterocycle compounds revealed potential antitumor agent against lung cancer cells.

08/01/2021

PubMed

 Unravelling the therapeutic potential of marine drugs as SARS-CoV-2 inhibitors: An insight from essential dynamics and free energy landscape.

04/23/2021

News Article

 Marine Biotechnology Market Size Forecast to Reach $7.3 Billion by 2026

11/05/2020

PubMed

 Is Crocin a Potential Anti-tumor Candidate Targeting Microtubules? Computational Insights From Molecular Docking and Dynamics Simulations.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions